Olmesartan Macleods (Olmesartan Medoxomil)

Olmesartan medoxil, the active ingredient in Olmesartan Macleods, is an Angiotensin II receptor blocker (ARB) presented as a tablet for oral use. It treats hypertension and is indicated for use in adult patients who require blood pressure control.

GNH USA supplies Olmesartan Macleods as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olmesartan Macleods is an ARB that lowers blood pressure by blocking the renin‑angiotensin system. - Hypertension: helps achieve target blood pressure and reduces cardiovascular risk. - Heart failure (post‑myocardial infarction): supports improved cardiac function when combined with standard therapy. - Diabetic nephropathy: slows progression of kidney damage associated with type 2 diabetes.

Olmesartan Macleods may cause a range of adverse reactions.

Common Side Effects: - Dizziness or light‑headedness - Headache - Fatigue - Nasal congestion - Diarrhoea - Cough

Serious or Rare Side Effects: - Angio‑edema (swelling of face, lips, tongue) - Severe hypotension - Acute kidney injury - Hyperkalemia (elevated potassium) - Liver enzyme elevations - Myocardial infarction (rare)

When prescribing Olmesartan Macleods, clinicians should consider several safety aspects. - Renal function monitoring: assess baseline creatinine and eGFR before initiating therapy. - Electrolyte balance: check serum potassium periodically, especially if combined with potassium‑sparing diuretics. - Pregnancy: avoid use during the second and third trimesters due to fetal toxicity. - Concomitant NSAID use: may blunt antihypertensive effect and increase renal risk. - Hypersensitivity: discontinue if rash or angio‑edema develops. - Store at below 25°C: keep in the original packaging, protect from moisture and light.

Olmesartan Macleods can interact with several medicines, requiring attention to dosage and monitoring.

Major Interactions (Avoid): - Dual renin‑angiotensin system blockade (e.g., ACE inhibitors, other ARBs): increased risk of hyperkalaemia and renal impairment. - Potassium‑rich supplements or salt substitutes: may cause dangerous hyperkalaemia.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may reduce antihypertensive efficacy and affect renal function. - Diuretics (especially thiazides): may enhance hypotensive effect. - Lithium: can increase serum lithium levels, risking toxicity. - Antifungal azoles (e.g., ketoconazole): may raise olmesartan concentrations. - CYP3A4 inhibitors (e.g., clarithromycin): modestly increase exposure.